Gary Meininger Selected Research

Symporters

12/2019	Diabetic ketoacidosis in patients with type 2 diabetes treated with sodium glucose co-transporter 2 inhibitors versus other antihyperglycemic agents: An observational study of four US administrative claims databases.
1/2017	Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study-Renal (CANVAS-R): A randomized, placebo-controlled trial.
1/2017	Longer-term safety and tolerability of canagliflozin in patients with type 2 diabetes: a pooled analysis.
6/2016	Impact of Age and Estimated Glomerular Filtration Rate on the Glycemic Efficacy and Safety of Canagliflozin: A Pooled Analysis of Clinical Studies.
5/2016	Effects of canagliflozin on body weight and body composition in patients with type 2 diabetes over 104 weeks.
5/2016	Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus from India.
3/2016	Efficacy and Safety of Canagliflozin in Individuals Aged 75 and Older with Type 2 Diabetes Mellitus: A Pooled Analysis.
11/2015	Achievement of treatment goals with canagliflozin in patients with type 2 diabetes mellitus: a pooled analysis of randomized controlled trials.
11/2015	Canagliflozin: a sodium glucose co-transporter 2 inhibitor for the treatment of type 2 diabetes mellitus.
9/2015	Efficacy and Safety of Canagliflozin Used in Conjunction with Sulfonylurea in Patients with Type 2 Diabetes Mellitus: A Randomized, Controlled Trial.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Gary Meininger Research Topics

Disease

37	Type 2 Diabetes Mellitus (MODY) 01/2020 - 12/2006
23	Body Weight (Weight, Body) 01/2018 - 12/2006
16	Infections 01/2017 - 08/2013
8	Hypoglycemia (Reactive Hypoglycemia) 01/2017 - 12/2006
7	Urinary Tract Infections (Urinary Tract Infection) 01/2017 - 09/2013
4	Weight Loss (Weight Reduction) 01/2018 - 06/2015
3	Diabetic Ketoacidosis (Ketoacidosis, Diabetic) 12/2019 - 09/2015
3	Chronic Renal Insufficiency 01/2019 - 01/2014
3	Cardiovascular Diseases (Cardiovascular Disease) 01/2016 - 08/2013
3	Insulin Resistance 12/2006 - 02/2002
2	Renal Insufficiency (Renal Failure) 01/2019 - 01/2017
2	Albuminuria 01/2019 - 01/2017
2	Hyperglycemia 11/2015 - 12/2006
2	Polyuria 12/2014 - 09/2013
2	Lipodystrophy 02/2004 - 02/2003
2	Hyperinsulinism (Hyperinsulinemia) 02/2003 - 08/2002
1	Pancreatitis 01/2020
1	Atherosclerotic Plaque (Atheroma) 01/2019
1	Heart Failure 01/2019
1	Kidney Diseases (Kidney Disease) 01/2019
1	Chronic Kidney Failure (Chronic Renal Failure) 01/2019
1	Myocardial Infarction 01/2019
1	Stroke (Strokes) 01/2019
1	Overweight 01/2018
1	Hypertension (High Blood Pressure) 01/2018
1	Bone Fractures (Bone Fracture) 01/2016
1	Hyperkalemia 12/2015
1	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 09/2015
1	Acidosis 09/2015
1	Ketosis 09/2015
1	Hypovolemia 03/2015
1	Body Weight Changes 06/2014
1	Diabetes Mellitus 05/2014
1	Edema (Dropsy) 06/2009

Drug/Important Bio-Agent (IBA)

35	CanagliflozinIBA 01/2020 - 08/2013
24	Glucose (Dextrose)FDA LinkGeneric 12/2019 - 12/2006
19	SodiumIBA 12/2019 - 08/2013
19	SymportersIBA 12/2019 - 08/2013
8	Sodium-Glucose Transport ProteinsIBA 01/2019 - 09/2013
8	Sodium-Glucose Transporter 2 InhibitorsIBA 01/2019 - 09/2013
8	Metformin (Glucophage)FDA LinkGeneric 01/2017 - 12/2006
6	Insulin (Novolin)FDA Link 12/2016 - 08/2002
5	Hypoglycemic Agents (Hypoglycemics)IBA 01/2020 - 09/2015
5	glimepiride (Amarel)FDA LinkGeneric 01/2017 - 09/2013
4	Glycated Hemoglobin (Glycosylated Hemoglobin)IBA 03/2016 - 05/2014
4	Sitagliptin Phosphate (Januvia)FDA Link 05/2015 - 12/2006
3	Blood Glucose (Blood Sugar)IBA 01/2017 - 08/2013
3	LipidsIBA 01/2016 - 02/2014
3	Hemoglobins (Hemoglobin)IBA 11/2015 - 02/2014
3	Triglycerides (Triacylglycerol)IBA 01/2015 - 09/2013
2	oxidized low density lipoproteinIBA 11/2015 - 02/2014
2	HDL CholesterolIBA 11/2015 - 09/2013
2	Protease Inhibitors (Protease Inhibitor)IBA 02/2003 - 08/2002
2	Fatty Acids (Saturated Fatty Acids)IBA 02/2003 - 02/2002
1	4- (4- dihexadecylaminostyryl)- N- methylpyridium (DiA)IBA 01/2019
1	darapladibIBA 01/2019
1	Alanine (L-Alanine)FDA Link 01/2019
1	Alanine Transaminase (SGPT)IBA 01/2019
1	Aspartate Aminotransferases (Aspartate Transaminase)IBA 01/2019
1	CreatinineIBA 01/2019
1	AlbuminsIBA 01/2019
1	Urea (Carbamide)FDA LinkGeneric 01/2016
1	DiureticsIBA 01/2016
1	PotassiumIBA 12/2015
1	LDL CholesterolIBA 11/2015
1	CholesterolIBA 01/2015
1	PlasticsIBA 06/2009
1	C-PeptideIBA 12/2006
1	ProinsulinIBA 12/2006
1	Growth Hormone (Somatotropin)IBA 02/2004
1	GhrelinIBA 02/2004
1	Somatostatin (Somatotropin Release-Inhibiting Factor)IBA 02/2004
1	Nonesterified Fatty Acids (NEFA)IBA 02/2004
1	acipimoxIBA 02/2003

Therapy/Procedure

12	Glycemic Control 01/2018 - 12/2006
8	Therapeutics 01/2019 - 12/2006
1	Transplantation 01/2019